Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin versus active comparator in pediatric skin infections
RBR-333g2hPhase 3Recruiting
- Sponsor
- Associação Hospitalar de Proteção à Infância Dr. Raul Carneiro
- Start
- Oct 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalbavancin, vancomycin, Oxacillin and flucloxacillin in skin and soft tissue infections (SSTIs), Staphylococcal Scalded Skin Syndrome (SSSS), impetigo and 7 more (3 arms), sponsored by Associação Hospitalar de Proteção à Infância Dr. Raul Carneiro. Started Oct 2016; status: recruiting.
02
Drugs
dalbavancinvancomycinOxacillinflucloxacillin
03
Conditions
skin and soft tissue infections (SSTIs)Staphylococcal Scalded Skin Syndrome (SSSS)impetigocutaneous abscessfuruncle
Beyond the preview
Go deeper on RBR-333g2h.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-333g2h.